<DOC>
	<DOCNO>NCT02581397</DOCNO>
	<brief_summary>This study evaluate non-inferiority Suppository Transpulmin Suppository Guaiacol compare Transpulmin Syrup treatment cough secretion infectious origin child two six year old . One third participant receive Suppository Transpulmin , one third receive Suppository Guaiacol last one third receive Transpulmin Syrup .</brief_summary>
	<brief_title>Transpulmin Suppository Guaiacol Compared Transpulmin Syrup Pediatric Participants With Productive Cough</brief_title>
	<detailed_description>Suppository Transpulmin , Suppository Guaiacol Transpulmin Syrup administer treatment cough secretion infectious origin . Each Suppository Transpulmin contain eucalyptol , menthol , camphor guaiacol . The main pharmacological activity eucalyptol occur respiratory tract , play expectorant action , fluidity antiseptic . There indication eucalyptol controller inflammatory mediator , intervene directly pathophysiology airway inflammation . On hand , menthol spasmolytic effect antiflatulent , antipruritic , analgesic antiemetic mucosa , show various study vitro vivo . In addition , effective many kind bacteria fungi . Camphor , turn , use respiratory dysfunction due secretolytic antispasmodic property ( bronchus ) . Finally , guaiacol classify expectorant believe promote increase sputum volume decrease viscosity , result effective coughing . However , despite extensive use recent decade , randomize control trial demonstrate efficacy tolerability , especially pediatric participant . Each Suppository Guaiacol contain guaiacol , whose action explain previously . Finally , Transpulmin Syrup contain guaifenesin , chemically glyceryl ether guaiacol . Thus , structure similar , pharmacological effect mechanisms action . The addition hydroxyl group increase hydrophilicity , make compound soluble , thus suitable pharmaceutical syrup form .</detailed_description>
	<mesh_term>Cough</mesh_term>
	<criteria>Participants guardian accept inclusion research participant study agree term propose Informed Consent Form / Informed Assent Form , sign Informed Consent Form Informed Assent Form guardians signature Informed Assent Form participant , possible ; Participants age ≥ ( great equal ) 02 year ≤ ( less equal ) 06 year , 11 month 29 day ethnicity , class social group ; Participants diagnose acute respiratory disease upper respiratory viral etiology ( UAI ) define medical researcher / subinvestigator , start less equal 48 hour prior inclusion study ; Participants productive cough , sputum lung snoring , participant rat score least sporadic / light specific score accordance paragraph 7.2.1 . ( Table 06 Protocol ) . Participants treat antibiotic ; Clinical presence bacterial infection upper airways / pulmonary ( bacterial sinusitis , pneumonia , etc . ) ; Participants unproductive cough ( dry cough ) ; Treatment immunosuppressant ; Participating research participate clinical trial protocol last twelve ( 12 ) month ( National Board Health Resolution 251 07 August 1997 , Part III , subitem J ) , unless investigator considers may direct benefit ; Participants require multidrug treatment ; Presence concomitant lung disease interfere , investigator 's opinion study result ; History hypersensitivity component study drug ( suppository Transpulmin , Suppository Guaiacol , Transpulmin syrup Paracetamol ) ; Subjects pathologies interfere pulmonary function , cerebral palsy muscular atrophy ; Any medical processing ( example : physiotherapy ) interfere study objective / participant safety ; Participants severe hepatic renal function disorder ; Participants xray chest compatible bacterial infection framework ; Participants hemogram suggestive bacterial infection ; Medical history / change laboratory test , clinical , physical / radiological , judge investigator , could compromise participant 's health reliability data ; Participants previous diagnosis diabetes mellitus type 01 type 02 ; Participants diagnose porphyria ; Participants prohibit medication describe item 6.9.1. Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cough</keyword>
	<keyword>expectorant</keyword>
	<keyword>upper respiratory tract infection</keyword>
	<keyword>respiratory tract infection</keyword>
	<keyword>antitussive agent</keyword>
</DOC>